Activity Description & Educational Objectives
In this activity, an expert in nephrology discusses recent and late-breaking data related to the management of anemia in patients with chronic kidney disease.
Upon completion of this activity, participants should be better able to:
- Discuss current trends in the treatment of anemia among hemodialysis patients with end-stage renal disease (ESRD) and discuss potential algorithms designed to improve the management of this cohort
- Employ late-breaking data related to established and emerging therapies for the treatment of anemia in patients with CKD and discuss their clinical implications with respect to recently updated practice guidelines
This activity has been designed to meet the educational needs of nephrologists and other clinicians involved in the treatment of chronic kidney disease.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: December 18, 2012 - December 17, 2013
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Michael J. Germain, MD
Professor of Medicine
Tufts University School of Medicine
Medical Director, Renal Transplantation
Baystate Medical Center
Michael J. Germain, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.
Grant/Research Support from Amgen Inc.
Speakers Bureau participant with Affymax, Inc. and Amgen Inc.
W. Brian Reeves, MD
Chief, Division of Nephrology
Penn State College of Medicine
W. Brian Reeves, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Novartis Corporation in the form of the Data and Safety Monitoring Board.
Grant/Research Support from Johnson & Johnson Services, Inc.
Shareholder in Amgen Inc.; AstraZeneca; and Medivation, Inc.
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education
Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5225-13-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by educational grants from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.